W Ludo Van Der Pol

List of Publications by Year
in descending order

87 papers	2,350 citations	201674 27 h-index	254184 43 g-index
88 all docs	88 docs citations	88 times ranked	2144 citing authors

#	Article	IF	Citations
1	Clinical outcome of CIDP oneÂyear after start of treatment: a prospective cohort study. Journal of Neurology, 2022, 269, 945-955.	3.6	7
2	Mastication in Patients with Spinal Muscular Atrophy Types 2 and 3 is Characterized by Abnormal Efficiency, Reduced Endurance, and Fatigue. Dysphagia, 2022, 37, 715-723.	1.8	9
3	Magnetic resonance reveals mitochondrial dysfunction and muscle remodelling in spinal muscular atrophy. Brain, 2022, 145, 1422-1435.	7.6	12
4	Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	5
5	Multiâ€parametric quantitative magnetic resonance imaging of the upper arm muscles of patients with spinal muscular atrophy. NMR in Biomedicine, 2022, 35, e4696.	2.8	3
6	MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes. Journal of Neurology, 2022, , 1.	3.6	1
7	Shortâ€term effect and effect on rate of lung function decline after surgery for neuromuscular or syndromic scoliosis. Pediatric Pulmonology, 2022, 57, 1303-1309.	2.0	2
8	Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. Orphanet Journal of Rare Diseases, 2022, 17, 70.	2.7	12
9	Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 2022, 20, 100.	5.5	15
10	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatology, The, 2022, 4, e338-e350.	3.9	88
11	Genetic, biochemical and clinical spectrum of patients with mitochondrial trifunctional protein deficiency identified after introduction of newborn screening in the Netherlands. Journal of Inherited Metabolic Disease, 2022, , .	3.6	5
12	Motor Unit and Capillary Recruitment During Fatiguing Arm-Cycling Exercise in Spinal Muscular Atrophy Types 3 and 4. Journal of Neuromuscular Diseases, 2022, , 1-13.	2.6	1
13	â€˜This battle, between your gut feeling and your mind. Try to find the right balanceâ€™: Parental experiences of children with spinal muscular atrophy during COVIDâ€19 pandemic. Child: Care, Health and Development, 2022, 48, 1062-1070.	1.7	2
14	Oscillometry: A substitute of spirometry in children with neuromuscular diseases?. Pediatric Pulmonology, 2022, 57, 1618-1624.	2.0	7
15	Short-term effect of air stacking and mechanical insufflationâ€“exsufflation on lung function in patients with neuromuscular diseases. Chronic Respiratory Disease, 2022, 19, 147997312210946.	2.4	5
16	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatology, The, 2022, 4, e417-e429.	3.9	33
17	Correlates of Fatigability in Patients With Spinal Muscular Atrophy. Neurology, 2021, 96, e845-e852.	1.1	20
18	Illness Perceptions in Pediatric Spinal Muscular Atrophy: Agreement between Children and their Parents, and its Association with Quality of Life. Journal of Developmental and Physical Disabilities, 2021, 33, 297-310.	1.6	8

#	Article	IF	Citations
19	Response to letter: A decision for life â€“ Treatment decisions in newly diagnosed families with spinal muscular atrophy. European Journal of Paediatric Neurology, 2021, 30, 103-104.	1.6	1
20	Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Rheumatology, 2021, 60, 785-801.	1.9	16
21	Parentsâ€™ perspectives on nusinersen treatment for children with spinal muscular atrophy. Developmental Medicine and Child Neurology, 2021, 63, 816-823.	2.1	7
22	Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance. Clinical Neurophysiology, 2021, 132, 800-807.	1.5	4
23	Second intravenous immunoglobulin dose in patients with Guillain-BarrÃ© syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283.	10.2	34
24	Quantitative magnetic resonance imaging of the brachial plexus shows specific changes in nerve architecture in chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and motor neuron disease. European Journal of Neurology, 2021, 28, 2716-2726.	3.3	6
25	High-resolution mapping identifies HLA class II associations with multifocal motor neuropathy. Neurobiology of Aging, 2021, 101, 79-84.	3.1	1
26	SMN1 Duplications Are Associated With Progressive Muscular Atrophy, but Not With Multifocal Motor Neuropathy and Primary Lateral Sclerosis. Neurology: Genetics, 2021, 7, e598.	1.9	0
27	Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiation. ACS Omega, 2021, 6, 35375-35388.	3.5	9
28	Psychological well-being in adults with spinal muscular atrophy: the contribution of participation and psychological needs. Disability and Rehabilitation, 2020, 42, 2262-2270.	1.8	9
29	Effect of mechanical insufflationâ€exsufflation in children with neuromuscular weakness. Pediatric Pulmonology, 2020, 55, 510-513.	2.0	12
30	Drug treatment for spinal muscular atrophy types II and III. The Cochrane Library, 2020, 1, CD006282.	2.8	26
31	Nerve ultrasound for diagnosing chronic inflammatory neuropathy. Neurology, 2020, 95, e1745-e1753.	1.1	32
32	Electrophysiology of fatigue in chronic inflammatory demyelinating polyneuropathy: Can it be useful?. Clinical Neurophysiology, 2020, 131, 2912-2914.	1.5	1
33	Clinical outcomes in multifocal motor neuropathy. Neurology, 2020, 95, e1979-e1987.	1.1	13
34	Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology, 2020, 95, e1988-e1998.	1.1	44
35	Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy. Brain Communications, 2020, 2, fcaa075.	3.3	32
36	Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscular Disorders, 2020, 30, 959-969.	0.6	15

#	Article	IF	Citations
37	Analysis of FUS, PFN2, TDP-43, and PLS3 as potential disease severity modifiers in spinal muscular atrophy. Neurology: Genetics, 2020, 6, e386.	1.9	13
38	Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study. Journal of Neuromuscular Diseases, 2020, 7, 323-330.	2.6	27
39	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. European Journal of Paediatric Neurology, 2020, 28, 38-43.	1.6	74
40	Relative hyperventilation in non-ventilated patients with spinal muscular atrophy. European Respiratory Journal, 2020, 56, 2000162.	6.7	2
41	Assessment of motor unit loss in patients with spinal muscular atrophy. Clinical Neurophysiology, 2020, 131, 1280-1286.	1.5	23
42	Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. Neurology, 2020, 94, e1470-e1479.	1.1	38
43	Nutritional ketosis improves exercise metabolism in patients with very longâ€chain acylâ€CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease, 2020, 43, 787-799.	3.6	26
44	Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies. Muscle and Nerve, 2020, 61, 779-783.	2.2	13
45	Natural history of lung function in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2020, 15, 88.	2.7	56
46	Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet Journal of Rare Diseases, 2020, 15, 75.	2.7	22
47	T₂ relaxationâ€time mapping in healthy and diseased skeletal muscle using extended phase graph algorithms. Magnetic Resonance in Medicine, 2020, 84, 2656-2670.	3.0	27
48	Population-based analysis of survival in spinal muscular atrophy. Neurology, 2020, 94, e1634-e1644.	1.1	54
49	Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. Journal of Neurology, 2019, 266, 2734-2742.	3.6	4
50	Nerve ultrasound can identify treatmentâ€responsive chronic neuropathies without electrodiagnostic features of demyelination. Muscle and Nerve, 2019, 60, 415-419.	2.2	29
51	Neuropathy associated with immunoglobulin M monoclonal gammopathy: A combined sonographic and nerve conduction study. Muscle and Nerve, 2019, 60, 263-270.	2.2	15
52	Bulbar Problems Self-Reported by Children and Adults with Spinal Muscular Atrophy. Journal of Neuromuscular Diseases, 2019, 6, 361-368.	2.6	23
53	Magnetic resonance imaging of the cervical spinal cord in spinal muscular atrophy. NeuroImage: Clinical, 2019, 24, 102002.	2.7	7
54	Validation of a Fast, Robust, Inexpensive, Two-Tiered Neonatal Screening Test algorithm on Dried Blood Spots for Spinal Muscular Atrophy. International Journal of Neonatal Screening, 2019, 5, 21.	3.2	10

#	Article	IF	Citations
55	Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology, 2019, 93, e149-e158.	1.1	45
56	Galectinâ€9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis and Rheumatology, 2019, 71, 1377-1390.	5.6	51
57	Participation and mental well-being of mothers of home-living patients with spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 321-329.	0.6	18
58	Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurology, 2019, 19, 21.	1.8	27
59	Impact of newborn screening for veryâ€longâ€chain acylâ€CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. Journal of Inherited Metabolic Disease, 2019, 42, 414-423.	3.6	36
60	Physical exercise training for type 3 spinal muscular atrophy. The Cochrane Library, 2019, 2019, CD012120.	2.8	26
61	Drug treatment for spinal muscular atrophy type I. The Cochrane Library, 2019, 12, CD006281.	2.8	11
62	Nerve ultrasound. Neurology, 2019, 92, .	1.1	32
63	High-resolution ultrasound in patients with Wartenbergâ€™s migrant sensory neuritis, a case-control study. Clinical Neurophysiology, 2018, 129, 232-237.	1.5	9
64	Muscle strength and motor function throughout life in a crossâ€sectional cohort of 180 patients with spinal muscular atrophy types 1câ€“4. European Journal of Neurology, 2018, 25, 512-518.	3.3	126
65	Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2â€“4 (SPACE trial). BMJ Open, 2018, 8, e019932.	1.9	31
66	A continuous repetitive task to detect fatigability in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2018, 13, 160.	2.7	17
67	The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. Health Policy, 2018, 122, 1287-1294.	3.0	11
68	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522.	10.2	95
69	MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability. Brain, 2017, 140, 2093-2103.	7.6	31
70	Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology, 2017, 88, 143-151.	1.1	135
71	Metalloprotease-mediated cleavage of PlexinD1 and its sequestration to actin rods in the motoneuron disease spinal muscular atrophy (SMA). Human Molecular Genetics, 2017, 26, 3946-3959.	2.9	17
72	A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy. European Journal of Neurology, 2017, 24, 1307-1313.	3.3	51

#	Article	IF	Citations
73	Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet Journal of Rare Diseases, 2017, 12, 67.	2.7	67
74	MRI shows thickening and altered diffusion in the median and ulnar nerves in multifocal motor neuropathy. European Radiology, 2017, 27, 2216-2224.	4.5	37
75	A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls. PLoS ONE, 2016, 11, e0167087.	2.5	32
76	Correlates of health related quality of life in adult patients with spinal muscular atrophy. Muscle and Nerve, 2016, 54, 850-855.	2.2	35
77	Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cellâ€“derived model. Annals of Neurology, 2016, 80, 71-88.	5.3	53
78	Comparative study of peripheral nerve Mri and ultrasound in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle and Nerve, 2016, 54, 1133-1135.	2.2	32
79	Nerve sonography to detect peripheral nerve involvement in vasculitis syndromes. Neurology: Clinical Practice, 2016, 6, 293-303.	1.6	30
80	Mandibular dysfunction as a reflection of bulbar involvement in SMA type 2 and 3. Neurology, 2016, 86, 552-559.	1.1	26
81	Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency. PLoS ONE, 2016, 11, e0147818.	2.5	35
82	<scp>RYR</scp>1â€related myopathies: a wide spectrum of phenotypes throughout life. European Journal of Neurology, 2015, 22, 1094-1112.	3.3	111
83	Cytokine profiles in multifocal motor neuropathy and progressive muscular atrophy. Journal of Neuroimmunology, 2015, 286, 1-4.	2.3	8
84	Bulbar muscle MRI changes in patients with SMA with reduced mouth opening and dysphagia. Neurology, 2014, 83, 1060-1066.	1.1	37
85	Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology, 2012, 79, 2050-2055.	1.1	85
86	Association of the FcÎ³ receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. Journal of Neuroimmunology, 2003, 144, 143-147.	2.3	25
87	Skeletal muscle training for spinal muscular atrophy type 3. The Cochrane Library, 0, , .	2.8	3